Aarti Industries Ltd · NSE:AARTIIND
Aarti Industries — Q2 FY21 Earnings Presentation
17 slides from Aarti Industries's earnings presentation, Nov 11, 2020
Slide 1: Exchange filing cover letter
AARTI @ INDUSTRIES LIMITED Ref. No.: AIL I B-4O I 2O2O I 159 November LL,2O2O To, To, Listing/Complianpce Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, uExchange Plaza",Plot No. C/1, Mumbai - 400 001. G Block Band
Slide 2: Q2 FY21 Results Presentation
AARTI INDUSTRIES LIMITED Q2 FY21 Results Presentation November 2020
Slide 3: Disclaimer
Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not
Slide 4: Agenda
Agenda 1 | At a glance 2 | Quarterly and Annual performance 3
Slide 5: Company Overview
Company Overview Overview Key Metrics A leading Speciality Chemicals company in Benzene based derivatives with integrated operations and high level of cost optimization 200+ 400+ 700+ Global Domestic Established by first generation technocrats in 1984 Products Customers Customers Pharma operat
Slide 6: Key Strengths
Key Strengths • Global Player in Benzene based Derivatives with Integrated Operations o Strong/Leadership position in key products and processes o Integrated operations across product chain of Benzene and Toluene o Ability to effectively use co-products and generate value-added products • Well Diver
Slide 7: Agenda
Agenda 1 | At a glance 2 | Quarterly & Annual performance 6
Slide 8: Chairman's Message
Chairman’s Message Commenting on the performance for Q2 FY21, Mr. Rajendra Gogri – Chairman & MD at Aarti Industries Limited said, “Our financial performance in Q2 has seen significant scale up compared to Q1. During the quarter, we were able to explore new markets for discretionary products resulti
Slide 9: Q2 FY21 P&L (Consolidated)
Q2 FY21 P&L (Consolidated) Particulars Y-o-Y Y-o-Y Q2 FY21 Q2 FY20 Q1 FY21 H1 FY21 H1 FY20 Strong revenue growth driven by expanding (Rs. Crore) (%) (%) volumes and greater traction from customers Gross Income from based on scale-up in value-added products 1,330 1,077 23.5% 1,035 2,366 2,212 6.9%
Slide 10: Speciality Chemical Revenue & EBIT
Speciality Chemical Revenue & EBIT Speciality Chemicals - Revenue 944 895 1,042 984 841 1,109 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Revenue Speciality Chemicals EBIT & EBIT % 22.6 23.9 20.6 17.5 15.4 17.1 213 214 215 172 130 190 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 EBIT EBIT % C
Slide 11: Q2 FY21 – Speciality Chemicals (Consolidated)
Q2 FY21 – Speciality Chemicals (Consolidated) Revenue Revenue Strong 24% topline growth on the back of higher volumes 1109 1839 1950 895 Plant operations hitting 90% levels One-time effort to push higher volumes for products in the discretionary spend basket at lower margins in non-regular mar
Slide 12: Pharma Revenue & EBIT
Pharma Revenue & EBIT Pharma - Revenue 191 182 176 206 194 222 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Revenue Pharma EBIT & EBIT % 23.3 25.5 18.5 20.4 16.7 17.4 32 34 36 36 45 57 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 EBIT EBIT % Consolidated basis; in Rs. Crore 11
Slide 13: Q2 FY21 – Pharma (Consolidated)
Q2 FY21 – Pharma (Consolidated) Revenue Revenue 222 416 182 373 Pharma business revenue grew by 22% YoY in Q2 Growth driven by increasing contribution from regulated markets and value-added products Q2 FY20 Q2 FY21 H1 FY20 H1 FY21 Record profit in the segment, margins expanded to 25% EBIT EBIT
Slide 14: Revenue Performance (Consolidated)
Revenue Performance (Consolidated) Revenue Export Deep engagement with Operating revenues have grown on the back of global customers in CAGR: 11% strong volume growth in 1,977 1,966 Speciality Chemicals and key business segments and 1,523 1,596 Pharma. In addition, some 1,431 4,705 4,621 part of dom
Slide 15: EBIT Performance (Consolidated)
EBIT Performance (Consolidated) EBIT Higher growth relative to revenue CAGR: 15% highlights value addition 932 952 delivered by AIL 663 615 542 421 FY16 FY17 FY18 FY19 FY20 H1 FY21 Speciality Chemicals Pharmacuticals CAGR: 13% CAGR: 37% 137 819 814 113 581 102 504 566 79 320 48 39 FY16 FY17 FY18 FY1
Slide 16: Contact Us
Contact Us For further information please log on to www.aarti-industries.com or contact: Mr. Chetan Gandhi / Mr. Raj Sarraf Aarti Industries Limited Tel: +91 22 6797 6666 Email: info@aarti-industries.com Shiv Muttoo / Shruti Joshi CDR India Tel: +91 98335 57572 / +91 75065 67349 Email: shiv@cdr-indi
Slide 17: Thank You
| PRODUCTIVE [WITH SAF [Sear TL ART SA